Contribution of cardio-vascular risk factors to depressive status in the PREDIMED-PLUS Trial. A cross-sectional and a 2-year longitudinal study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
07
2021
accepted:
13
02
2022
entrez:
13
4
2022
pubmed:
14
4
2022
medline:
16
4
2022
Statut:
epublish
Résumé
Cardio-vascular disease and depression are thought to be closely related, due to shared risk factors. The aim of the study was to determine the association between cardio-vascular risk (CVR) factors and depressive status in a population (55-75 years) with metabolic syndrome (MetS) from the PREDIMED-Plus trial. Participants were classified into three groups of CVR according to the Framingham-based REGICOR function: (1) low (LR), (2) medium (MR) or (3) high/very high (HR). The Beck Depression Inventory-II (BDI-II) was used to assess depressive symptoms at baseline and after 2 years. The association between CVR and depressive status at baseline (n = 6545), and their changes after 2 years (n = 4566) were evaluated through multivariable regression models (logistic and linear models). HR women showed higher odds of depressive status than LR [OR (95% CI) = 1.78 (1.26, 2.50)]. MR and HR participants with total cholesterol <160 mg/mL showed higher odds of depression than LR [OR (95% CI) = 1.77 (1.13, 2.77) and 2.83 (1.25, 6.42) respectively)] but those with total cholesterol ≥280 mg/mL showed lower odds of depression than LR [OR (95% CI) = 0.26 (0.07, 0.98) and 0.23 (0.05, 0.95), respectively]. All participants decreased their BDI-II score after 2 years, being the decrease smaller in MR and HR diabetic compared to LR [adjusted mean±SE = -0.52±0.20, -0.41±0.27 and -1.25±0.31 respectively). MR and HR participants with total cholesterol between 240-279 mg/mL showed greater decreases in the BDI-II score compared to LR (adjusted mean±SE = -0.83±0.37, -0.77±0.64 and 0.97±0.52 respectively). Improving cardiovascular health could prevent the onset of depression in the elderly. Diabetes and total cholesterol in individuals at high CVR, may play a specific role in the precise response. International Standard Randomized Controlled Trial (ISRCTN89898870).
Sections du résumé
BACKGROUND
Cardio-vascular disease and depression are thought to be closely related, due to shared risk factors. The aim of the study was to determine the association between cardio-vascular risk (CVR) factors and depressive status in a population (55-75 years) with metabolic syndrome (MetS) from the PREDIMED-Plus trial.
METHODS AND FINDINGS
Participants were classified into three groups of CVR according to the Framingham-based REGICOR function: (1) low (LR), (2) medium (MR) or (3) high/very high (HR). The Beck Depression Inventory-II (BDI-II) was used to assess depressive symptoms at baseline and after 2 years. The association between CVR and depressive status at baseline (n = 6545), and their changes after 2 years (n = 4566) were evaluated through multivariable regression models (logistic and linear models). HR women showed higher odds of depressive status than LR [OR (95% CI) = 1.78 (1.26, 2.50)]. MR and HR participants with total cholesterol <160 mg/mL showed higher odds of depression than LR [OR (95% CI) = 1.77 (1.13, 2.77) and 2.83 (1.25, 6.42) respectively)] but those with total cholesterol ≥280 mg/mL showed lower odds of depression than LR [OR (95% CI) = 0.26 (0.07, 0.98) and 0.23 (0.05, 0.95), respectively]. All participants decreased their BDI-II score after 2 years, being the decrease smaller in MR and HR diabetic compared to LR [adjusted mean±SE = -0.52±0.20, -0.41±0.27 and -1.25±0.31 respectively). MR and HR participants with total cholesterol between 240-279 mg/mL showed greater decreases in the BDI-II score compared to LR (adjusted mean±SE = -0.83±0.37, -0.77±0.64 and 0.97±0.52 respectively).
CONCLUSIONS
Improving cardiovascular health could prevent the onset of depression in the elderly. Diabetes and total cholesterol in individuals at high CVR, may play a specific role in the precise response. International Standard Randomized Controlled Trial (ISRCTN89898870).
Identifiants
pubmed: 35417452
doi: 10.1371/journal.pone.0265079
pii: PONE-D-21-24745
pmc: PMC9007355
doi:
Substances chimiques
Cholesterol
97C5T2UQ7J
Banques de données
ISRCTN
['ISRCTN89898870']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0265079Déclaration de conflit d'intérêts
JS-S reports serving on the board of and receiving grant support through his institution from the International Nut and Dried Fruit Council and Eroski Foundation. JS-S also reports serving in the Executive Committee of the Instituto Danone Spain and on the Scientific Committee of the Danone International Institute. He has received research support from Patrimonio Comunal Olivarero, Spain, and Borges S.A., Spain. He has also received consulting fees or travel expenses from Danone, Eroski Foundation, Instituto Danone—Spain, and Abbot Laboratories. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Bipolar Disord. 2000 Mar;2(1):60-4
pubmed: 11254022
Rev Esp Cardiol. 2011 May;64(5):385-94
pubmed: 21482004
Clin Nutr. 2019 Oct;38(5):1995-2001
pubmed: 30497694
Cardiovasc Diabetol. 2020 Nov 3;19(1):187
pubmed: 33143700
Eur Heart J. 2017 May 07;38(18):1426-1435
pubmed: 26705390
Health Psychol. 2001 Mar;20(2):112-9
pubmed: 11315728
Mol Psychiatry. 2020 Jul;25(7):1477-1486
pubmed: 30886334
J Affect Disord. 2016 Dec;206:55-67
pubmed: 27466743
World Psychiatry. 2017 Feb;16(1):111
pubmed: 28127930
Psychosom Med. 1991 Nov-Dec;53(6):634-42
pubmed: 1758948
Psychiatry Res. 2020 Jan 21;285:112802
pubmed: 32036152
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
J Med Life. 2016 Apr-Jun;9(2):120-5
pubmed: 27453739
J Am Heart Assoc. 2017 Mar 13;6(3):
pubmed: 28288977
Diabetes Care. 2011 Apr;34(4):904-9
pubmed: 21346185
Int J Epidemiol. 2019 Apr 1;48(2):387-388o
pubmed: 30476123
Acta Psychiatr Scand. 2019 Dec;140(6):552-562
pubmed: 31587258
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jun 8;92:405-411
pubmed: 30779936
Rev Neurol. 2009 Mar 1-15;48(5):261-4
pubmed: 19263395
Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
Int J Cardiol. 2019 Jan 1;274:358-365
pubmed: 29921514
Circ Res. 2019 Mar;124(5):779-798
pubmed: 30817261
J Affect Disord. 2013 Sep 25;150(3):736-44
pubmed: 23870425
Proc Nutr Soc. 2016 May;75(2):139-46
pubmed: 26898781
World J Biol Psychiatry. 2010 Dec;11(8):922-33
pubmed: 20950120
Diabetologia. 2010 Dec;53(12):2480-6
pubmed: 20711716
Med Sci Sports Exerc. 2000 Aug;32(8):1431-7
pubmed: 10949009
Circulation. 2010 Feb 2;121(4):586-613
pubmed: 20089546
Am J Epidemiol. 1994 Jun 15;139(12):1197-209
pubmed: 8209878
JAMA Psychiatry. 2020 Oct 1;77(10):1052-1063
pubmed: 32520341
Trends Cardiovasc Med. 2020 Apr;30(3):170-176
pubmed: 31109802
Psychiatry Res. 2000 Oct 30;96(2):167-73
pubmed: 11063789
Int J Epidemiol. 2013 Aug;42(4):1012-4
pubmed: 24062287
Heart. 2017 May;103(9):649-650
pubmed: 27940968
Adv Exp Med Biol. 2018;1065:389-411
pubmed: 30051398
Pol Arch Intern Med. 2021 Jun 29;131(6):497-498
pubmed: 34184851
Front Psychiatry. 2016 Mar 21;7:33
pubmed: 27047396
Int J Obes (Lond). 2012 Apr;36(4):595-602
pubmed: 21654630
Arch Intern Med. 2010 Nov 22;170(21):1884-91
pubmed: 21098346